A panel of a mitogenic (PDGF), biochemical (albumin) and demographic (age) parameters for the non-invasive assessment of hepatic fibrosis

Attallah, A.M.; Albannan, Mohamed S.; Omran, M M; Zayed, Rania A.; Saif, Sameh; Farid, Alyaa; Hassany, Mohamed; Yosry, Ayman; Omran, Dalia

doi:10.1080/09674845.2019.1600325

Cited by 4 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whilst many of these papers also report standard LFTs and AFP, and the occasional haematology, other serum markers, often in combination, may be important in determining the extent of hepatic fibrosis. These include a panel of platelet-derived growth factor, albumin and age that out-performed LFTs and AFP [10], prealbumin, cholesterase and retinol-binding protein, which also identify hepatic encephalopathy [11], and the ratio of gammaglutamyl transpeptidase to platelet count [12].…”

Section: The Livermentioning

confidence: 99%

British Journal of Biomedical Science in 2019. What have we learned?

Blann

2019

British Journal of Biomedical Science

View full text Add to dashboard Cite

In 2019 the British Journal of Biomedical Science published 40 articles in the various disciplines that comprise biomedical science. These were one review, 22 original articles and 17 'In Brief' short reports. Of those citing original data, the majority were in cellular pathology (14 papers), clinical chemistry (9 papers), and microbiology (6 papers: 4 in bacteriology and 2 in virology). There were 3 papers in haematology and 2 in andrology, whilst 5 papers crossed traditional discipline boundaries (such as the molecular genetics of IL6, liver function tests, and hepatocellular carcinoma). Over two-thirds of papers used techniques in molecular genetics. The present report will summarise key aspects of these publications that are of greatest relevance to laboratory scientists.

show abstract

Section: The Livermentioning

confidence: 99%

British Journal of Biomedical Science in 2019. What have we learned?

Blann

2019

British Journal of Biomedical Science

View full text Add to dashboard Cite

show abstract

“…Histopathology is the traditional benchmark for the determination of liver brosis stage, but needle liver biopsy procedure is invasive and has some limitations including cost, risk of complications, sampling errors, inaccurate representation of unevenly distributed liver disease as the sample of the liver biopsy parallels a fraction of 1/50,000th of the whole liver [5]. Noninvasive methods for hepatic brosis staging in chronic HCV patients including physical (imaging techniques) and biological (serum biomarkers) have become increasingly available over the last few decades [7,8,[10][11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

Cairo University Fibrosis Index (CUFI): A MicroRNA Based Score for Accurate Prediction of Hepatic Fibrosis: A Biopsy Controlled Study

Abdel-Haleem

Zekri²,

Moniem

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: The exact identification of liver fibrosis is mandatory for customizing therapy and controlling complications. The aim of the current study is to measure the ability to circulate miRNAs; in the diagnosis of hepatic fibrosis.Methods: Routine laboratory, liver biopsy, and histopathological investigations were done on seventy HCV patients. In addition, estimation of HCV-RNA, serum micro RNA (miRNA)-122, 221, 192, 224, 375, and 885 were done by PCR. To assess the ability of each miRNA, the area under the receiver operating characteristics (AUC) curves were plotted. Significant miRNA were analyzed by linear regression analysis in a stepwise pattern to develop a score for pointing out significant fibrosis. Moreover, the following scores were calculated: aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio (AAR), aspartate to platelet ratio index (APRI), FIB-4 score, Hui index, Fibrosis Index (FI), Fibro-Q, Fibro-Alfa Biotechnology Research Center (BRC) score, and Gotebörg University Cirrhosis Index (GUCI).Results: Patients with significant and advanced fibrosis have significantly lower miR-122. MiR-122, FIB4, total bilirubin, and miR-855 proved to be independent predictors of significant fibrosis in univariate analysis. A novel score; Cairo University Fibrosis Index (CUFI) based on microRNA 122, FIB4, bilirubin, and microRNA 855 were formulated for the identification of significant liver fibrosis. The AUC of the score, for predicting significant and advanced hepatic fibrosis was 0.85 and 0.81. This AUC was higher than those of other common fibrosis scores.Conclusion: Cairo University Fibrosis Index proved to be better than other existing scores in assessing fibrosis in chronic hepatitis C (CHC) patients.

show abstract

“…Noninvasive methods for hepatic fibrosis staging in chronic HCV patients including physical (imaging techniques) and biological (serum biomarkers) have become increasingly available over the last few decades [7,8,[10][11][12][13][14]. Micro RNAs (miRNAs) are small non-coding RNAs with an average length of 22 nucleotides that control translation and transcription of many genes [15].…”

Section: Introductionmentioning

confidence: 99%

Cairo University fibrosis index (CUFI): A score based on microRNA for diagnosis of significant hepatic fibrosis

Abdel-Haleem

Zekri

Moniem

et al. 2022

ijhs

View full text Add to dashboard Cite

Introduction: Identification of HCV- induced liver fibrosis is mandatory for tailoring therapy, and management of complications. The current study evaluated the accuracy of circulating miRNAs; in diagnosis of hepatic fibrosis. Patients and methods: Seventy HCV patients were subjected to routine laboratory investigations, HCV-RNA, serum miRNA-122, 221, 192, 224 , 375, and 885 by PCR, liver biopsy and calculation of the following scores: aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio (AAR), aspartate to platelet ratio index (APRI), FIB-4 score, Hui index, Fibrosis Index (FI), Fibro-Q , Fibro-Alfa Biotechnology Research Center (BRC) score and Gotebörg University Cirrhosis Index (GUCI). Results: Patients with significant and advanced fibrosis have significantly lower miR-122 (P < 0.0001 and P= 0.007, respectively). miR-122, bilirubin and miR-855 were found to be independent predictors of significant fibrosis in univariate analysis. A novel score; Cairo University Fibrosis Index (CUFI) based on microRNA 122, bilirubin and microRNA 855 were formulated for predicting significant liver fibrosis. The AUC of this score, for predicting significant and advanced hepatic fibrosis was 0.83 and 0.80 respectively. This AUC was higher than those of other fibrosis scores. Conclusion: Cairo University Fibrosis Index is better than the existing scores in assessing fibrosis in chronic HCV patients.

show abstract

A panel of a mitogenic (PDGF), biochemical (albumin) and demographic (age) parameters for the non-invasive assessment of hepatic fibrosis

Cited by 4 publications

References 33 publications

British Journal of Biomedical Science in 2019. What have we learned?

British Journal of Biomedical Science in 2019. What have we learned?

Cairo University Fibrosis Index (CUFI): A MicroRNA Based Score for Accurate Prediction of Hepatic Fibrosis: A Biopsy Controlled Study

Cairo University fibrosis index (CUFI): A score based on microRNA for diagnosis of significant hepatic fibrosis

Contact Info

Product

Resources

About